Clariant Will Expand Plant in Lewiston, ME To Produce More Medical Plastic Compounds


  • Announcement made at Pharmapack Europe and MD&M West
  • New extrusion line to be operational in Q4 2017
  • Additional capacity for MEVOPUR® medical-compliant materials
Muttenz, February 1, 2017 – Clariant, a world leader in specialty chemicals, announces it will expand its plant in Lewiston, ME, and install a new compounding line to help meet growing demand for pre-colored medical plastic compounds that are supplied under the MEVOPUR® brand name. The new capacity will come on-line in Q4 2017.

The news is being released at Pharmapack Europe 2017 in Paris (February 1-3) where Clariant is exhibiting on stand C35/C37, and at MD&M West 2017 (booth #2450), which is being held in Anaheim, CA, February 7 - 9.

The new compounding line, built around a new 70-mm extruder, will be able produce larger batch sizes (e.g.: 3000 to 6000kg /6000 to 12000lbs or larger) at high throughput rates. Production will focus on materials such as polyolefins, ABS, PC and PC alloys as well as specialty resins like TPU, and cyclic olefins. The EN-ISO13485 (2012) certified site in Lewiston is also being expanded to improve process-flow and material-handling.

"Over the last five years," says Steve Duckworth, Head of Global Segment Healthcare Polymer Solutions, "Clariant has pioneered the development of masterbatches for the healthcare sector. These are color and additive concentrates that are added to natural polymers during molding or extrusion of finished products. However, in some cases, medical processors may prefer to use a pre-colored compound instead, perhaps for ease of handling or because of technical difficulties in the molding or extrusion process. And yet, they have the same need for Controlled, Consistent and Compliant materials."

Clariant's MEVOPUR materials are offered for applications in medical devices and pharmaceutical packaging, where strict regulations on materials and change control apply. The Lewiston plant is one of three global sites designed and operated to produce materials used in medical devices and pharmaceutical packaging. The other two facilities are located in Malmö, Sweden, and Singapore. All are certified to EN:ISO13485 (2012) and can use the same validated raw-material ingredients and processes so that the same products can be produced at any of the sites. Raw materials are pre-tested to standards commonly required for device and drug filings, e.g.: USP <88> ('USP Class VI') and ISO10993.

This new capacity complements equipment and plant investments aimed at compounding engineering resins and high-temperature polymers and, most recently, completion of a special installation in Lewiston for processing fluoropolymers such as FEP, ETFE, and PVDF.

Clariant already operates several smaller lines – in Lewiston and Clariant's other MEVOPUR facilities -- which produce masterbatches and pre-colored compounds in lot sizes ranging from 25 to 2500kg/50 to 5000 lbs. In addition, production capacity for compounds is also being added during the first half of 2017 in Singapore, to handle increasing demand of color compounds for local and international customers. These small- and medium-sized lots are in high demand, especially in the medical market, since many resin producers have discontinued or severely curtailed their custom-color offerings in anything smaller than full-truck or railcar quantities.

Request to Clariant

Please enter your contact information so we are able to process your request. Thank you for your interest.

Contact Us

Contact Us

Online Communications Team

Your Name

 

Your Email

Phone

Your Company

Country

Message

Disclaimer:
This information corresponds to the present state of our knowledge and is intended as a general description of our products and their possible applications. Clariant makes no warranties, express or implied, as to the information’s accuracy, adequacy, sufficiency or freedom from defect and assumes no liability in connection with any use of this information. Any user of this product is responsible for determining the suitability of Clariant’s products for its particular application.<br />
<br />
* Nothing included in this information waives any of Clariant’s General Terms and Conditions of Sale, which control unless it agrees otherwise in writing. Any existing intellectual/industrial property rights must be observed. Due to possible changes in our products and applicable national and international regulations and laws, the status of our products could change. Material Safety Data Sheets providing safety precautions, that should be observed when handling or storing Clariant products, are available upon request and are provided in compliance with applicable law. You should obtain and review the applicable Material Safety Data Sheet information before handling any of these products. For additional information, please contact Clariant.<br />
<br />
* For sales to customers located within the United States and Canada the following applies in addition: No express or implied warranty is made of the merchantability, suitability, fitness for a particular purpose or otherwise of any product or service.<br />
<br />
© Trademark of Clariant registered in many countries.<br />
® 2019 Clariant International Ltd 

You are about to leave the Clariant domain

The link you activated will take you outside the Clariant site in about 10 seconds. If you want to stop this, press "Cancel".